Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 28, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction involving Mr. R Bondy, who acquired a beneficial interest in 1 Ordinary Share. The share was purchased under a Personal Equity Plan on March 26, 2007, at a price of GBP 13.95.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly details the share acquisition in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the identity of Mr. R Bondy and his role within GlaxoSmithKline plc.
- Confirm the transaction date of March 26, 2007, and the purchase price of GBP 13.95 per share.
- Note that this filing does not contain financial performance data for the quarter or year.